findmyKOL
Clinical trialNCT06488950RecruitingEarly phase 1Interventional

A Study of TIL in Advanced Solid Tumors (DFGD)

SponsorShanghai Juncell TherapeuticsEnrollment30Advanced Solid TumorEffects of ImmunotherapyTreatment Side EffectsTumor Infiltrating Lymphocytes
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China
  • Third Affiliated Hospital of Naval Medical University

    Shanghai, China

    Qian ZhangWenlong Yu
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Apr 2023
Primary completion
30 Jun 2026
Completion
30 Jun 2027
Last update posted
16 Dec 2025
Registered enrollment
30
Registry id
NCT06488950
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.